Palvella Therapeutics Wins 2026 PACT Healthcare & Life Sciences Company of the Year Award
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
WAYNE, Pa., May 15, 2026 Palvella Therapeutics announced new positive Phase 2 TOIVA trial data for QTORINâ„¢ rapamycin in...
